Vita Life Sciences's EBIT per Share for the
six
months ended in Dec. 2025 was A$0.14.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.26.
During the past 12 months, the average EBIT per Share Growth Rate of Vita Life Sciences was 17.60% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 7.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 8.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 11.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Vita Life Sciences's EBIT per Share or its related term are showing as below:
ASX:VLS'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -10.9 Med: 7.5 Max: 66.5
Current: 7.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Vita Life Sciences was 66.50% per year. The lowest was -10.90% per year. And the median was 7.50% per year.
ASX:VLS's 3-Year EBIT Growth Rate is ranked worse than 50.19% of 809
companies
in the Drug Manufacturers industry
Industry Median: 7.6
vs ASX:VLS: 7.50
Vita Life Sciences (ASX:VLS) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Vita Life Sciences EBIT per Share Related Terms
Vita Life Sciences EBIT per Share Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.26
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences (ASX:VLS) has a EBIT per Share of A$0.26 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Vita Life Sciences and its competitors. According to the industry distribution chart, Vita Life Sciences ranks #406 out of 809 companies in the Drug Manufacturers industry, placing it in the top 50.2%.
Is Vita Life Sciences' EBIT per Share too high?
Vita Life Sciences' current EBIT per Share is A$0.26. Based on the distribution chart, Vita Life Sciences ranks #406 out of 809 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vita Life Sciences has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' EBIT per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #406 out of 809 companies for EBIT per Share. This places Vita Life Sciences in the lower half of its industry. The industry median EBIT per Share is 7.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.60, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current EBIT per Share is A$0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.48, compared to a current price of A$2.45 — trading 1.2% below its estimated fair value. The current EBIT per Share is A$0.26. Vita Life Sciences' overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current EBIT per Share is A$0.26 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be undervalued.
The current stock price of A$2.45 is trading 1.2% below its estimated GF Value™ of A$2.48.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
EBIT per Share: A$0.26
GF Value™: A$2.48 vs. price of A$2.45 (1.2% below fair value)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
85GF Score
Get the complete analysis for ASX:VLS
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
